Comparative Pharmacology
Head-to-head clinical analysis: HISTALOG versus HISTAMINE PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HISTALOG versus HISTAMINE PHOSPHATE.
HISTALOG vs HISTAMINE PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Histalog (betazole) is a histamine H2 receptor agonist that stimulates gastric acid secretion by directly acting on parietal cells in the stomach.
Histamine phosphate acts as a direct agonist at histamine H1 and H2 receptors, leading to vasodilation, increased capillary permeability, bronchoconstriction, and stimulation of gastric acid secretion.
1.7 mg subcutaneously once, as a single dose for gastric acid secretion testing.
0.01 mg subcutaneous once for diagnosis of achlorhydria; 0.02-0.04 mg/kg subcutaneous for challenge in pheochromocytoma (rarely used).
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2 hours in adults with normal renal function; may be prolonged in renal impairment.
Terminal elimination half-life is approximately 1–2 minutes; rapid due to enzymatic metabolism by histamine N-methyltransferase and diamine oxidase. Clinical context: ultra-short duration requires continuous IV infusion or repeated administration for sustained effect.
Primarily renal excretion of unchanged drug (approximately 80-90%) with the remainder as metabolites; biliary excretion accounts for <10%.
Renal (primarily as metabolites); less than 2% excreted unchanged in urine. Biliary/fecal excretion negligible.
Category C
Category C
Histamine Analog (Diagnostic)
Histamine Analog (Diagnostic)